Novo Nordisk's U.S. stock pre-market rose over 8%, clinical trials show its weight loss drug Amycretin reduces weight by 22%
I'm PortAI, I can summarize articles.
Novo Nordisk's U.S. stock pre-market rose over 8% due to the clinical trial results of its weight loss drug Amycretin, which showed that patients lost 22% of their weight over 36 weeks. The company plans to further develop Amycretin for adults who are overweight or obese
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Wallstreetcn The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments